Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.
Biomarker and diagnostic research for ophthalmic herpes zoster has been reported in the published literature.
No clinical trials have been registered for ophthalmic herpes zoster.
119 publications have been identified in PubMed for ophthalmic herpes zoster. Research spans Case Report / Case Series (39%), Review / Meta-Analysis (22%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 47 | 39% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 2:58 PM UTC
26 |
22% |
Disease patterns and progression | 22 | 18% |
Laboratory research | 9 | 8% |
Clinical study results | 8 | 7% |
Other research | 4 | 3% |
Testing and diagnosis research | 2 | 2% |
New treatment approaches | 1 | 1% |
Gu W (2026). [PMID: 41754410](https://pubmed.ncbi.nlm.nih.gov/41754410/). *Pathogens*. [Review / Meta-Analysis]
Lu KC (2026). [PMID: 41632695](https://pubmed.ncbi.nlm.nih.gov/41632695/). *QJM*. [Other]
Meghana NR (2026). [PMID: 42255721](https://pubmed.ncbi.nlm.nih.gov/42255721/). *Cureus*. [Case Report / Case Series]
Li CF (2026). [PMID: 41632686](https://pubmed.ncbi.nlm.nih.gov/41632686/). *QJM*. [Epidemiology / Natural History]
Lee S (2026). [PMID: 41775120](https://pubmed.ncbi.nlm.nih.gov/41775120/). *Vaccine*. [Clinical Trial Publication]
Maleki A (2026). [PMID: 41835798](https://pubmed.ncbi.nlm.nih.gov/41835798/). *Ann Transl Med*. [Other]
Mihalache A (2026). [PMID: 41966483](https://pubmed.ncbi.nlm.nih.gov/41966483/). *Ophthalmology*. [Epidemiology / Natural History]
Kawasaki S (2026). [PMID: 41033999](https://pubmed.ncbi.nlm.nih.gov/41033999/). *Intern Med*. [Case Report / Case Series]
Alegre-Ituarte V (2026). [PMID: 41498708](https://pubmed.ncbi.nlm.nih.gov/41498708/). *Ophthalmology*. [Case Report / Case Series]
Sidiropoulou M (2026). [PMID: 41702223](https://pubmed.ncbi.nlm.nih.gov/41702223/). *Transplant Rev (Orlando)*. [Review / Meta-Analysis]
AI-curated news mentioning ophthalmic herpes zoster
Updated Jul 30, 2026
The future of rare disease clinical development is being shaped by regulatory innovation and adaptive trial designs, emphasizing the need for operational strategies to tackle challenges like limited patient populations and complex endpoints. Advances in artificial intelligence and global patient recruitment are also key to enhancing the development process.